Metraipolis › archive › dc_ef619e3df393

Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database — Europe PMC PMID:40894206

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40894206
DOI
10.3389/fphar.2025.1622339
License (as archived)
solo-consultazione
Archived
2026-11-10T14:43:39.421Z
SHA-256 of the archived text
2fb32af1cdcb1587d7d5221f057ce54d8da1f1a59357d578eb5281d3eb9dbbd6
Stable URL of this page
https://metraipolis.com/documento/dc_ef619e3df393

How to cite

Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database — Europe PMC PMID:40894206 — Europe PMC (en), https://europepmc.org/article/MED/40894206 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_ef619e3df393 (Metraipolis archive dc_ef619e3df393, sha256 2fb32af1cdcb1587d7d5221f057ce54d8da1f1a59357d578eb5281d3eb9dbbd6)
BibTeX
@misc{dcef619e3df393,
  title = {Real-world study on adverse drug reactions of pembrolizumab in endometrial cancer treatment: insights from the FAERS database — Europe PMC PMID:40894206},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40894206},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_ef619e3df393; sha256 2fb32af1cdcb1587d7d5221f057ce54d8da1f1a59357d578eb5281d3eb9dbbd6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40894206. Agents can read the archived copy with the MCP tool read_document.